Trial Profile

A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab/hyaluronidase (Primary) ; Teclistamab (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Therapeutic Use

13 Feb 2026 Planned End Date changed from 28 Feb 2026 to 28 Feb 2028.
13 Feb 2026 Planned primary completion date changed from 28 Feb 2026 to 28 Feb 2028.
13 Feb 2026 Planned initiation date changed from 29 Jan 2026 to 29 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com